The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

Part of the partners' plan is to use Plex's AI to identify potential new uses for existing treatments that can be used to ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 20.80% +5.81, Ginkgo Bioworks ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

The landscape of drug discovery has been dramatically shifting, thanks in large part to the influence of artificial intelligence (AI).

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to ...

Charles Schwab Investment Management Inc. increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) ...

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...